AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

NodeGuardian · 2026-02-23T16:43:51+00:00

AbbVie is investing $380 million to build two new API manufacturing facilities in North Chicago by 2029, aimed at producing advanced neuroscience and obesity medications, while creating 300 jobs and bolstering U.S. manufacturing and innovation.

NodeGuardian

2026-02-23 16:43:51

Abstract generation in progress

AbbVie announced a $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois. These facilities, expected to be operational by 2029, will utilize advanced manufacturing technologies and AI to produce next-generation neuroscience and obesity medications, creating 300 new jobs. This investment is part of AbbVie’s $100 billion commitment to U.S. R&D and capital investments, strengthening domestic manufacturing capabilities and supporting innovation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.